CefpiromeThird Party Manufacturing in India

Cefpirome works by rapidly crossing the outer membrane of Gram-negative bacteria due to its zwitterionic structure and binding with high affinity to essential penicillin-binding proteins. This binding inhibits the final transpeptidation step of peptidoglycan synthesis, disrupting cell wall assembly and leading to rapid bacterial cell lysis. It exhibits high resistance to degradation by many chromosome- and plasmid-mediated beta-lactamases, helping preserve its activity against many cephalosporin-resistant pathogens. It is highly effective and well-tolerated.

Therapeutic Uses

• Bacteremia and Septicemia: Used for the urgent empirical treatment of life-threatening systemic bloodstream infections.
• Complicated Urinary Tract Infections: Treats severe upper tract infections and renal abscesses caused by multi-drug resistant Gram-negative rods.
• Severe Lower Respiratory Infections: Indicated for hospital-acquired pneumonia and acute exacerbations of chronic lung diseases.

Why Manufacturers Choose Cefpirome

Its structural resistance to beta-lactamases and high stability make it an important option for managing severe nosocomial infections. Utilizing Cefpirome third party manufacturing in India helps brands secure a dependable supply for clinical and institutional buyers. Prepared using premium CAS number 84957-29-9 active ingredients, our partner facilities operate under cleanroom conditions meeting WHO-GMP certified standards to guarantee zero particulate contamination.